A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Clinical trial NCT00537511 · TERMINATED

Trial details

NCT number: NCT00537511
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Small Cell

Start date: 2008-02-01
Primary completion: 2010-11-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.